Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with neoadjuvant radiochemotherapy in locally advanced KRAS wild-type rectal cancer
2009-009277-10Phase 2Terminated
- Sponsor
- Heidelberg University Hospital
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in rectal adenocarcinoma and rectal cancer, sponsored by Heidelberg University Hospital. Primary endpoint: Histopathological complete response rate. Started Nov 2010; status: terminated.
02
Drugs
panitumumab
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2009-009277-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009277-10.